Abstract:Circulation Research, Volume 132, Issue 11, Page 1521-1545, May 26, 2023. Epidemiologic studies detected an inverse relationship between HDL (high-density lipoprotein) cholesterol (HDL-C) levels and atherosclerotic cardiovascular disease (ASCVD), identifying HDL-C as a major risk factor for ASCVD and suggesting atheroprotective functions of HDL. However, the role of HDL-C as a mediator of risk for ASCVD has been called into question by the failure of HDL-C–raising drugs to reduce cardiovascular events in clinical trials. Progress in understanding the heterogeneous nature of HDL particles in terms of their protein, lipid, and small RNA composition has contributed to the realization that HDL-C levels do not necessarily reflect HDL function. The most examined atheroprotective function of HDL is reverse cholesterol transport, whereby HDL removes cholesterol from plaque macrophage foam cells and delivers it to the liver for processing and excretion into bile. Indeed, in several studies, HDL has shown inverse associations between HDL cholesterol efflux capacity and ASCVD in humans. Inflammation plays a key role in the pathogenesis of atherosclerosis and vulnerable plaque formation, and a fundamental function of HDL is suppression of inflammatory signaling in macrophages and other cells. Oxidation is also a critical process to ASCVD in promoting atherogenic oxidative modifications of LDL (low-density lipoprotein) and cellular inflammation. HDL and its proteins including apoAI (apolipoprotein AI) and PON1 (paraoxonase 1) prevent cellular oxidative stress and LDL modifications. Importantly, HDL in humans with ASCVD is oxidatively modified rendering HDL dysfunctional and proinflammatory. Modification of HDL with reactive carbonyl species, such as malondialdehyde and isolevuglandins, dramatically impairs the antiatherogenic functions of HDL. Importantly, treatment of murine models of atherosclerosis with scavengers of reactive dicarbonyls improves HDL function and reduces systemic inflammation, atherosclerosis development, and features of plaque instability. Here, we discuss the HDL antiatherogenic functions in relation to oxidative modifications and the potential of reactive dicarbonyl scavengers as a therapeutic approach for ASCVD.

Progress of High Density Lipoprotein in Resisting Atherosclerosis

Progress of Cardioprotective Effects of High Density Lipoprotein: Function and Mechanism

Using High-density Lipoprotein with New Therapeutic Techniques

Re-understanding the Relationship of High-Density Lipoprotein with Atherosclerosis Vascular Disease

High-density Lipoprotein and Inflammation and Its Significance to Atherosclerosis

HDL and arteriosclerosis: beyond reverse cholesterol transport

Apolipoprotein A1-Related Proteins and Reverse Cholesterol Transport in Antiatherosclerosis Therapy: Recent Progress and Future Perspectives

Advances in the Study of the Antiatherogenic Function and Novel Therapies for HDL

Antiatherogenic Effects Of High-Density Lipoproteins: Mechanisms

Bridging the Gap Between the Bench and Bedside: Clinical Applications of High-density Lipoprotein Function

HDL Function and Atherosclerosis: Reactive Dicarbonyls as Promising Targets of Therapy

High-Density Lipoprotein Subfractions Remodeling: A Critical Process for the Treatment of Atherosclerotic Cardiovascular Diseases

HDL and Immunomodulation: an Emerging Role of HDL Against Atherosclerosis

Preparation and Activity Analysis of Recombinant Human High-Density Lipoprotein

High-Density Lipoprotein and Heart Failure

High-density Lipoprotein Affects Antigen Presentation by Interfering with Lipid Raft: a Promising Anti-Atherogenic Strategy

HDL and immunomodulation: an emerging role of HDL against atherosclerosis.

Τhe Antioxidant Function of HDL in Atherosclerosis

The Functional Role of Lipoproteins in Atherosclerosis: Novel Directions for Diagnosis and Targeting Therapy

Recombinant High-Density Lipoproteins and Their Use in Cardiovascular Diseases.

High-density Lipoprotein (HDL) Dysfunction and the Future of HDL